Charcot-Marie-Tooth disease (CMT) is a neurological disorder, but it is not a life-threatening disease. Charcot-Marie-Tooth disease does not affect the brain but causes damage to the peripheral nerves; tracts of nerve cell fibres that connect the brain and spinal cord to muscles and sensory organs. Charcot-Marie-Tooth disease is not curable, but the disease generally progresses slowly, and it does not affect expected life span. The therapy includes physical therapy, occupational therapy and orthopedic devices.
The drug candidates in the pipeline of Charcot-Marie-Tooth disease include, but are not limited to, ACE-083, PXT3003 and MD1003. Some of the companies having drugs for Charcot-Marie-Tooth disease in pipeline are Addex Therapeutics Ltd., Affectis Pharmaceuticals AG, Lead Discovery Center GmbH and Pharnext SA.
The report provides a comprehensive understanding of the pipeline activities covering all drug candidates under various stages of development, with detailed analysis of pipeline and clinical trials. Pipeline analysis of drugs by phases includes product description and development activities including information about clinical results, designations, collaborations, licencing, grants, technology and others.